Page 611 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

CHAPTER 26 Tumors of the Endocrine System 589

136. Yoshida O, Kutara K, Seki M, et al.: Preoperative differential diag- 157. Daniel G, Mahony OM, Markovich JE, et al.: Clinical findings,
nosis of canine adrenal tumors using triple-phase helical computed diagnostics and outcome in 33 cats with adrenal neoplasia (2002-
tomography, Vet Surg 45:427–435, 2016. 2013), J Feline Med Surg 18:77–84, 2016.
VetBooks.ir 137. Llabres-Diaz FJ, Dennis R: Magnetic resonance imaging of the 158. Djajadiningrat-Laanen S, Galac S, Kooistra H: Primary hyperaldo-
steronism: expanding the diagnostic net, J Feline Med Surg 13:641–
presumed normal canine adrenal glands, Vet Radiol Ultrasound
650, 2011.
44:5–19, 2003.
138. Labelle P, Kyles AE, Farver TB, et al.: Indicators of malignancy 159. Javadi S, Djajadiningrat-Laanen SC, Kooistra HS, et al.: Primary
of canine adrenocortical tumors: histopathology and proliferation hyperaldosteronism, a mediator of progressive renal disease in cats,
index, Vet Pathol 41:490–497, 2004. Domest Anim Endocrinol 28:85–104, 2005.
139. Scavelli TD, Peterson ME, Matthiesen DT: Results of surgi- 160. Djajadiningrat-Laanen SC, Galac S, Cammelbeeck SE, et al.:
cal treatment for hyperadrenocorticism caused by adrenocortical Urinary aldosterone to creatinine ratio in cats before and after
neoplasia in the dog: 25 cases (1980-1984), J Am Vet Med Assoc suppression with salt or fludrocortisone acetate, J Vet Intern Med
189:1360–1364, 1986. 22:1283–1288, 2008.
140. Whittemore JC, Preston CA, Kyles AE, et al.: Nontraumatic rup- 161. Djajadiningrat-Laanen SC, Galac, Boeve MH, et al.: Evaluation
ture of an adrenal gland tumor causing intra-abdominal or retroper- of the oral fludrocortisone suppression test for diagnosing pri-
itoneal hemorrhage in four dogs, J Am Vet Med Assoc 219:329–333, mary hyperaldosteronism in cats, J Vet Intern Med 27:1493–1499,
2001. 2013.
141. Behrend EN, Kemppainen RJ: Diagnosis of canine hyperadre- 162. Matsuda M, Behrend EN, Kemppainen R, et al.: Serum aldoste-
nocorticism, Vet Clin North Am Small Anim Pract 31:985–1001, rone and cortisol concentrations before and after suppression with
2001. fludrocortisone in cats: a pilot study, J Vet Diagn Invest 27:361–
142. Dolera M, Malfassi L, Pavesi S, et al.: Volumetric-modulated arc 368, 2015.
stereotactic radiotherapy for canine adrenocortical tumours with 163. Koutinas CK, Soubasis NC, Djajadiningrat-Laanen SC, et al.: Uri-
vascular invasion, J Small Anim Pract 57:710–717, 2016. nary aldosterone/creatinine ratio after fludrocortisone suppression
143. Kintzer PP, Peterson ME: Diagnosis and management of canine consistent with PHA in a cat, J Am Anim Hosp Assoc 51:338–341,
cortisol-secreting adrenal tumors, Vet Clin North Am Small Anim 2015.
Pract 27:299–307, 1997. 164. Moore LE, Biller DS, Smith TA: Use of abdominal ultrasonogra-
144. Feldman EC, Nelson RW, Feldman MS, et al.: Comparison of phy in the diagnosis of primary hyperaldosteronism in a cat, J Am
mitotane treatment for adrenal tumor versus pituitary-dependent Vet Med Assoc 217:213–215, 2000.
hyperadrenocorticism in dogs, J Am Vet Med Assoc 200:1642–1647, 165. Schulman RL: Feline primary hyperaldosteronism, Vet Clin North
1992. Am Small Anim Pract 40:353–359, 2010.
145. Kintzer PP, Peterson ME: Mitotane treatment of 32 dogs with 166. Ash RA, Harvey AM, Tasker S: Primary hyperaldosteronism in the
cortisol-secreting adrenocortical neoplasms, J Am Vet Med Assoc cat: a series of 13 cases, J Feline Med Surg 7:173–182, 2005.
205:54–61, 1994. 167. Lo AJ, Holt DE, Brown DC, et al.: Treatment of aldosterone-
146. Feldman EC: Evaluation of twice-daily lower-dose trilostane treat- secreting adrenocortical tumors in cats by unilateral adrenalectomy:
ment administered orally in dogs with naturally occurring hyperad- 10 cases (2002-2012), J Vet Intern Med 28:137–143, 2014.
renocorticism, J Am Vet Med Assoc 238:1441–1451, 2011. 168. Flood SM, Randolph JF, Gelzer AR, et al.: Primary hyperaldoste-
147. Eastwood JM, Elwood CM, Hurley KJ: Trilostane treatment of a ronism in two cats, J Am Anim Hosp Assoc 35:411–416, 1999.
dog with functional adrenocortical neoplasia, J Small Anim Pract 169. MacKay AD, Holt PE, Sparkes AH: Successful surgical treatment
44:126–131, 2003. of a cat with primary aldosteronism, J Feline Med Surg 1:117–122,
148. Benchekroun G, de Fornel-Thibaud P, Lafarge S, et al.: Trilostane 1999.
therapy for hyperadrenocorticism in three dogs with adrenocortical 170. Rose SA, Kyles AE, Labelle P, et al.: Adrenalectomy and caval
metastasis, Vet Rec 163:190–192, 2008. thrombectomy in a cat with primary hyperaldosteronism, J Am
149. Helm JR, McLauchlan G, Boden LA, et al.: A comparison of fac- Anim Hosp Assoc 43:209–214, 2007.
tors that influence survival in dogs with adrenal-dependent hyper- 171. Gilson SD, Withrow SJ, Wheeler SL, et al.: Pheochromocytoma in
adrenocorticism treated with mitotane or trilostane, J Vet Intern 50 dogs, J Vet Intern Med 8:228–232, 1994.
Med 25:251–260, 2011. 172. Barthez PY, Marks SL, Woo J, et al.: Pheochromocytoma in dogs:
150. Arenas C, Melian C, Perez-Alenza MD: Long-term survival of 61 cases (1984-1995), J Vet Intern Med 11:272–278, 1997.
dogs with adrenal-dependent hyperadrenocorticism: a comparison 173. Galac S: Pheochromocytoma. In Ettinger SJ, Feldman EC, Cote
between mitotane and twice daily trilostane treatment, J Vet Intern E, editors: Textbook of veterinary internal medicine, ed 8, St. Louis,
Med 28:473–480, 2014. 2017, Elsevier, pp 1838–1843.
151. Rijnberk A, Kooistra HS, van Vonderen IK, et al.: Aldosteronoma 174. Reusch CE: Pheochromocytoma and multiple endocrine neoplasia.
in a dog with polyuria as the leading symptom, Domest Anim Endo- In Feldman EC, Nelson RW, Reusch CE, et al.: Canine and feline
crinol 20:227–240, 2001. endocrinology, ed 4, St. Louis, 2015, Elsevier, pp 521–554.
152. Behrend EN, Weigand CM, Whitley EM, et al.: Corticosterone- 175. Herrera MA, Mehl ML, Kass PH, et al.: Predictive factors and
and aldosterone-secreting adrenocortical tumor in a dog, J Am Vet the effect of phenoxybenzamine on outcome in dogs undergoing
Med Assoc 226:1662–1666, 2005. adrenalectomy for pheochromocytoma, J Vet Intern Med 22:1333–
153. Machida T, Uchida E, Matsuda K, et al.: Aldosterone-, corticoste- 1339, 2008.
rone- and cortisol-secreting adrenocortical carcinoma in a dog: case 176. Rosenstein DS: Diagnostic imaging in canine pheochromocytoma,
report, J Vet Med Sci 70:317–320, 2008. Vet Radiol Ultrasound 41:499–506, 2000.
154. Gojska-Zygner O, Lechowski R, Zygner W: Functioning unilateral 177. Berry CR, DeGrado TR, Nutter F, et al.: Imaging of pheochromo-
adrenocortical carcinoma in a dog, Can Vet J 53:623–625, 2012. cytoma in 2 dogs using p-[18F] fluorobenzylguanidine, Vet Radiol
155. Frankot JL, Behrend EN, Sebestyen P, et al.: Adrenocortical carci- Ultrasound 43:183–186, 2002.
noma in a dog with incomplete excision managed long-term with 178. Head LL, Daniel GB: Scintigraphic diagnosis-an unusual presenta-
metastasectomy alone, J Am Anim Hosp Assoc 48:417–423, 2012. tion of metastatic pheochromocytoma in a dog, Vet Radiol Ultra-
156. Behrend EN: Non-cortisol-secreting adrenocortical tumors and sound 45:574–576, 2004.
incidentalomas. In Ettinger SJ, Feldman EC, Cote E, editors: Text- 179. Doss JC, Grone A, Capen CC, et al.: Immunohistochemical local-
book of veterinary internal medicine, ed 8, St. Louis, 2017, Elsevier, ization of chromogranin A in endocrine tissues and endocrine
pp 1819–1825. tumors of dogs, Vet Pathol 35:312–315, 1998.